Tatva Chintan Pharma Chem Ltd

- There is no mention of any current or planned fundraising through debt or equity in the transcript. - The company discusses capacity expansions and new product commercialization mostly funded through existing resources and potential capex internally decided. - For some scalable products (e.g., agro intermediates), additional rounds of capex might be considered later, but no specific fundraising plan is shared. - Focus remains on organic growth, capacity utilization, and new product development without reference to external fundraising activities.

- A new plant is being designed at Jolva, with groundbreaking planned for January-February 2026 to accommodate a large scalable agrochemical product. - This new facility will help overcome production bottlenecks for newly commercialized agro and pharma intermediates. - Additional capex rounds may be considered for scaling up certain agro products as demand grows. - Plant scale changes are underway to enable delivery of commercial batches for semiconductor chemicals, targeted for Q4 of the current financial year. - Ongoing investment in R&D for advanced products in semiconductor and electrolyte salt spaces. - The new plant block is expected to be available for commercial production starting January 2026 to improve operational efficiency and capacity utilization.

- **SDA Segment**: Strong volume uptick expected from 2026 onward as new customers onboard; pricing bottomed out with expected increase, leading to improved EBITDA margins to 20-22% within two quarters. - **Agro Products**: Anticipated 1.5x volume growth next financial year and another 1.5x growth in the following year. New agro intermediate with significant domestic demand expected to become a key product by 2027. - **Electrolyte Salts**: Revenue projected to reach around INR15 crore in the current year, scaling up to 10% of total revenue by FY'27 with consistent volume growth and regular dispatches. - **Pharma and Agro Intermediates**: Four agro and four pharma molecules expected to reach full potential in 2-3 years, collectively addressing a revenue potential of INR300-350 crore. - **Semiconductor Chemicals**: Gradual commercialization expected starting end of 2027 or early 2028, with meaningful business in 2-3 years. - **Overall**: Continued volume growth supported by new plant commissioning in January 2026, enhancing capacity and cost efficiency.

- Strong growth expected in SDA segment with volumes set to increase significantly from 2026 due to new customer onboarding and Euro 7 norms-driven demand. - EBITDA margins in SDA anticipated to improve to 20-22% as plant occupancy reaches full capacity in next 2 quarters. - Electrolyte Salt segment projected to grow steadily, reaching around INR15 crores revenue in current year and rising to ~10% of total revenue by FY '27. - Pharma and agro intermediates expected to scale with INR300-350 crores potential revenue at full capacity in 2-3 years. - Semiconductor chemicals segment targeting commercialization from late 2027 / early 2028, with margins comparable or better than SDA. - Current low ROCE (~4% pre-tax) to improve with rising plant utilization; EBITDA from new plant could reach INR175 crores. - Overall, firm outlook on revenue and earnings growth driven by capacity utilization, product innovation, and new commercializations over medium term.

- The company is currently executing trial orders for individual solar plant energy shields in the energy storage system segment, indicating the beginning of commercialization. - Small-scale commercial orders have been executed for hybrid batteries used in automotive applications, with positive customer feedback. - Goods in transit for the PASC (Phase Transfer Catalysts) segment have increased from INR16-17 crores last quarter to INR26 crores this quarter, reflecting an active order pipeline. - New large-scale agro intermediate commercialization has commenced, with production activities progressing as planned. - Validation batches for new pharma and agro intermediates are underway, with commercialization expected from December 2025 to the second half of 2026. - The semiconductor product pipeline includes products in piloting, with expected revenues ranging INR50-100 crores. - New customers onboarding in SDA (Structure Directing Agents) expected to drive meaningful business starting 2026. - Current electrolyte salt business has transitioned from inconsistent to regular supply, with consistent orders and expected revenue growth starting Q3 FY26.